Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-75. [Šekerija M]
Autori: Allemani C,
Matsuda T,
Di Carlo V,
Harewood R,
Matz M,
Niksic MGodina: 2018
Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017;144(2):396-404. [Šekerija M]
Autori: Matz M,
Coleman MP,
Carreira H,
Salmeron D,
Chirlaque MD,
Allemani C,
CONCORD Working GroupGodina: 2017
Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405-413]. Gynecol Oncol. 2017;147(3):726. [Šekerija M]
Autori: Matz M,
Coleman MP,
Sant M,
Chirlaque MD,
Visser O,
Gore M,
Allemani C,
the CONCORD Working GroupGodina: 2017
(Šekerija M) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
Autori: Allemani C,
Weir HK,
Carreira H,
Harewood R,
Spika D,
Wang XSGodina: 2015
Erratum to “Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 396-404]. Gynecol Oncol. 2017;147(3):725. [Šekerija M]
Autori: Matz M,
Coleman MP,
Carreira H,
Salmeron D,
Chirlaque MD,
Allemani C,
CONCORD Working GroupGodina:
The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol. 2017;144(2):405-13. [Šekerija M]
Autori: Matz M,
Coleman MP,
Sant M,
Chirlaque MD,
Visser O,
Gore M,
Allemani C,
the CONCORD Working GroupGodina:
